General Biotechnology

Evergreen strategies are getting smarter—and so do the teams trying to beat them.
For years, “brand” companies have used a familiar playbook: extend exclusivity not by inventing a cure, but by tightening the legal perimeter around an existing one. New …

Biopharma bizdev teams don’t lose deals because they can’t sell. They lose deals because they’re pitching the wrong time horizon.
In licensing, partnering, and BD strategy, timing is everything—but most teams still treat packaging as an afterthought: a…

Consumers don’t just pay for medicine. They pay for certainty.
That’s the uncomfortable truth behind “branded generics”—a category that often gets dismissed as a marketing relic, when in reality it reflects a deeper economic reality: when patients and …

The real fight doesn’t start when the patent is granted—it starts when it’s about to expire.
For years, the pharmaceutical playbook has been framed as a straight line: patent protection buys time, generic entry follows, and everyone moves on. But the m…

Pharma doesn’t just “win” patents—it engineers time.
In a world where blockbuster drugs face relentless pressure from generics and biosimilars, the real competitive advantage often isn’t the original patent grant. It’s what comes after: the ability to …

The cliff is coming. The question is whether you can see it.
In pharma, “the cliff” isn’t a metaphor—it’s a calendar. It’s the moment exclusivity ends, the moment generic competition becomes legally possible, and the moment pricing power can evaporate …

Generic drugs are supposed to be boring. But the path to generic profits is anything but. A new analysis from DrugPatentWatch lays out a stark contrast between two playbooks: the U.S. “niche strategy” and India’s “mass market model.” Both can print mon…

Most drug companies still treat the 505(b)(2) and 505(b)(1) pathways like interchangeable “regulatory routes.” They aren’t.
And that misunderstanding is expensive—measured in months, dollars, and, ultimately, the credibility of your development plan wi…

Patent gaps aren’t “accidents.” They’re design features—often hiding in plain sight.
For years, the industry has talked about patent cliffs like they’re weather: unpredictable, unavoidable, and mostly outside anyone’s control. But the real story is m…

The 20-year patent is supposed to be a finish line. In pharma, it’s often just the starting gun.
For years, the public narrative has been simple: drug patents last 20 years, and once they expire, competition arrives. But the reality—especially in the U…